Alphamab Oncology (HKG:9966) appointed David Ng as chief financial officer, succeeding Fei Wang, who resigned due to other work commitments.
Ng joins Alphamab Oncology from Hutchmed (HKG:0013), where he was head of investor relations and capital strategies, according to a Thursday Hong Kong bourse filing.